NEXT GENERATION

Non-Metastatic Castration-Resistant Prostate Cancer

The latest prostate cancer research is turning its focus on the M0 space. M0 prostate cancer is a stage where the disease is non-metastatic but has become resistant to hormone therapy. Many therapeutic options for castration-resistant prostate cancer are approved and used for metastatic castration-resistant prostate cancer (mCRPC), but fewer options exist for those with non-metastatic (NM) CRPC.

PLATINUM LECTURES

Challenging Cases in Advanced Prostate Cancer: nmCRPC

R. Jonathan Henderson, MD
Jun 2020

R. Jonathan Henderson, MD, a urologist with Regional Urology, LLC, discusses an unusual case of non-metastatic castration-resistant prostate cancer (nmCRPC) with a panel featuring Laurence Klotz, MD, FRCSC, Daisaku Hirano, MD, and Michael S. Cookson, MD.

Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score

Fred Saad, MD, FRCS
Nov 2019

Fred Saad, MD, FRCS, presents findings from an exploratory analysis he led and presented at the American Urological Association's 2019 Annual Meeting. The study evaluated the association between DECIPHER genomic classifier (GC) score and metastasis-free survival following apalutamide treatment in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients included in the SPARTAN study.

NEED TO KNOW

M0 Space and The SPARTAN Trial

Eric J. Small, MD, FASCO
Apr 2018

Eric J. Small, MD, FASCO, defines nonmetastatic castration-resistant prostate cancer, or M0 disease. He then discusses the design, implementation, and results of the SPARTAN trial, which he also presented at the 2018 Genitourinary Cancers Symposium. The study tested the efficacy of apalutamide in men with M0 disease.

An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC

Maha H. Hussain, MD, FACP, FASCO
Mar 2018

Dr. Maha H.A. Hussain, MBChB, reviews the PROSPER trial, which tested the efficacy and safety of enzalutamide in the setting of nonmetastatic CRPC. Following her summary, she and Dr. E. David Crawford, MD, engage in a question and answer session.

ADDITIONAL LECTURES

Summarizing the RADAR Guidelines

Phillip J. Koo, MD
Jun 2019

E. David Crawford, MD, reviews the findings and recommendations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) I and II working groups. Phillip J. Koo, MD, then discusses the rationale for RADAR III and the expansion in recommendations from the first two iterations, focusing on updates regarding next generation imaging.

Navigating the M0 Space

E. David Crawford, MD
Jun 2019

E. David Crawford, MD, reviews the historical developments in androgen deprivation therapy (ADT) for prostate cancer and the emergence of the non-metastatic castration-resistant, or M0, prostate cancer. He then describes future directions for treatment options for these patients with a focus on androgen pathway inhibitors.

PCa Commentary | Volume 131 – February 2019

Edward Weber, MD
Feb 2019

This Commentary will discuss these developments and the current indications for enzalutamide (ENZ) and new studies of ENZ as monotherapy

Immunotherapy for Castration Resistant Prostate Cancer

Daniel P. Petrylak, MD
Nov 2018

Daniel P. Petrylak, MD, provides a brief update on data regarding sipuleucel-T for castration resistant prostate cancer (CRPC), as well as pembrolizumab for microsatellite instability (MSI) -high metastatic prostate cancer patients.

Advanced Disease A Real Need for Shared Care

Advanced Disease — A Real Need for Understanding and Shared Care

Daniel P. Petrylak, MD
Apr 2018

Daniel Petrylak, MD, stresses the importance of a multidisciplinary approach when treating prostate cancer. Not only does this mean involving urologists, oncologists, and primary care physicians, but also involving nutritionist, mental health professionals, and pain management experts for maintaining patients’ QOL.

AR-V7 in Castration Resistant Prostate Cancer

Emmanuel S. Antonarakis, MD
Mar 2018

Dr. Emmanuel Antonarakis discusses treating chemo-naive metastatic hormone-sensitive prostate cancer and then discusses the impact of AR-V7 in CRPC.